Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RIN 150 · 1 trial · 1 indication
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) was reported for rifampicin and isoniazid.
Cmax was reported for rifampicin and isoniazid.
| Arm | Type | Description |
|---|---|---|
| Test | EXPERIMENTAL | RIN 150 contains 150 rifampicin and 75 mg isoniazid |
| Reference | ACTIVE_COMPARATOR | Individual references of rifampicin and isoniazid |
| Name | Type | Description |
|---|---|---|
| RIN 150 | DRUG | Each subject will receive a single oral dose of 4 fixed dose combination tablets (RIN 150) each contains 150 rifampicin and 75 mg isoniazid. |
| reference drugs | DRUG | Each subject will receive a single oral dose of 4 x 150 mg rifampicin capsules and 3 x 100 mg isoniazid capsules. |
Inclusion Criteria: * Healthy male or female, 21 to 55 years of age, body weight no less than 55 kg, with a signed and dated informed consent document and is willing and able to comply with all scheduled visits, treatment plan, laboratory tests and other study procedures. Exclusion Criteria: * Ev...
RIN 150 is an investigational small molecule developed by Pfizer, Inc. (ticker PFE). It has been studied in a Phase 1 bioequivalence trial comparing a fixed dose combination formulation with RIN 150 and individual reference drugs in healthy volunteers. The specific therapeutic indication for RIN 150 has not been disclosed.
RIN 150 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 bioequivalence study of RIN 150 conducted in Singapore.
RIN 150 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The completed study was an active-controlled, randomized bioequivalence trial in healthy volunteers.
RIN 150 has been evaluated in one completed Phase 1 trial, NCT02014272, titled a bioequivalence study comparing a fixed dose combination formulation, RIN 150 and individual reference drugs in healthy volunteers. The trial enrolled 28 participants in Singapore and was active-controlled and randomized.
The RIN 150 bioequivalence trial, NCT02014272, was a Phase 1, randomized, active-controlled study in healthy volunteers aged 21 years and older of all sexes. It enrolled 28 participants in Singapore and compared a fixed dose combination formulation with RIN 150 and individual reference drugs. The study is completed.